CDP Sample Record
A N
097119294
J A
Biological Abstracts Vol. 097 Iss. 006 Ref. 069169.
A U
Farci P. Mandas A. Coiana A. Lai M E. Desmet V. Van Eyken P. Gobi Y. Caruso L. Scaccabarozzi S. et al.
I N
Hepatitis Viruses Section, Lab. Infectious Diseases, Natl. Inst. Allergy Infectious Diseases, Natl. Inst.
Health, Build. 7, Rm 200, 9000 Rockville Pike, Bethesda, MD 20892, USA.
T I
Title: Treatment of chronic hepatitis D with interferon alfa-2a.
S O
New England Journal of Medicine 330 (2). 1994. 88-94.
K W RESEARCH ARTICLE. HUMAN. INTERFERON-ALPHA-2A. ANTIVIRAL-DRUG. HORMONE-DRUG.
ALANINE AMINOTRANSFERASE. VIRAL RNA. POST-TREATMENT RELAPSE.
C C
*Clinical Biochemistry General Methods and Applications [10006]
*Enzymes-Physiological Studies [10808]
*Pathology, General and Miscellaneous-Inflammation and Inflammatory Disease [12508]
*Pathology, General and Miscellaneous-Therapy (1971- ) [12512]
*Metabolism-Proteins, Peptides and Amino Acids [13012]
*Metabolism-Nucleic Acids, Purines and Pyrimidines [13014]
*Digestive System-Pathology [14006]
*Blood, Blood-Forming Organs and Body fluids-Lymphatic Tissue and Reticuloendothelial
System [15008]
*Endocrine System-General [17002]
*Pharmacology-Clinical Pharmacology (1972-) [22005]
*Pharmacology-Digestive System [22014]
*Pharmacology-Endocrine System [22016]
*Medical and Clinical Microbiology-Virology [36006]
*Chemotherapy-Antiviral Agents [38506]
Biochemical Studies-Nucleic Acids, Purines and Pyrimidines [10062]
Biochemical Studies-Proteins, Peptides and Amino Acids [10064]
Biochemical Studies-Carbohydrates [10068]
Genetics of Bacteria and Viruses [31500]
B C
Biosystematic Codes/Super Taxonomic Groups:
Animal-Viruses-General (1993- ) [02600]
Hominidae 86215
MICROORGANISMS. VIRUSES. ANIMALS. CHORDATES. VERTEBRATES. MAMMALS. PRIMATES.
H U M A N S .
A B
ABSTRACT Background and Methods. Chronic hepatitis D is a severe and rapidly progressive liver
disease for which no therapy has been proved effective. To evaluate the efficacy of treatment with
interferon, we studied 42 patients with chronic hepatitis D who were randomly assigned to receive
either 9 million or 3 million units of recombinant interferon alfa-2a (three times a week for 48
weeks) or no treatment. Results. By the end of the treatment period, serum alanine
aminotransferase values had become normal in 10 of 14 patients receiving 9 million units (71
percent), as compared with 4 of 14 treated with 3 million units (29 percent, P = 0.029) and 1 of 13
untreated controls (8 percent, P = 0.001). Seven patients treated with the higher dose of interferon
(50 percent) had a complete response (normal levels of alanine aminotransferase and no detectable
serum hepatitis delta virus (HDV) RNA), as compared with three of those who received the lower
dose (21 percent, P = 0.118), and none of the controls (P = 0.004). Treatment with 9 million units of
interferon was associated with a marked improvement in the histologic findings (reduced periportal
necrosis and portal and lobular inflammation), whereas in the untreated controls there was
considerable histologic deterioration. In 5 of the 10 patients treated with 9 million units of
interferon whose alanine aminotransferase values became normal, the biochemical responses
persisted for up to 4 years (mean, 39 months), but the effects of treatment on viral replication were
not sustained. In contrast, none of those who received 3 million units and none of the untreated
controls had a sustained biochemical or virologic response. Conclusions. In about half the patients
q
q
q
L G
E n g l i s h .
P T
A R T I C L E .
I S
0 0 2 8 - 4 7 9 3 .
E W 9 4 1 2
YR 1 9 9 4
2 6
S a m p l e R e c o r d s b y S e a r c h S y s t e m
